Phase 2 Cardiomyopathy Trial, Recruiting (NCT06965621)

Phase 2 Cardiomyopathy Trial, Recruiting NCT06965621 Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT06965621 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have heart failure caused by reduced blood flow to the heart (ischemic cardiomyopathy) that is currently stable
Your heart's pumping ability is significantly reduced, meaning tests show your heart pumps out 35% or less of blood with each beat
You have had an implanted defibrillator device (ICD — a small device placed in your chest to help control dangerous heart rhythms) for at least 12 months

Who may not be able to join:

Your heart or coronary artery disease is currently unstable or not well controlled
You do not have an implanted defibrillator device (ICD)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: K. Lance Gould, MD, Professor of Medicine, McGovern Medical School, UTHealth

Phone: 713-704-2489

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06965621

Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase: Phase 2

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: 713-704-2489

More information: https://clinicaltrials.gov/study/NCT06965621

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have heart failure caused by reduced blood flow to the heart (ischemic cardiomyopathy) that is currently stable
Your heart's pumping ability is significantly reduced, meaning tests show your heart pumps out 35% or less of blood with each beat
You have had an implanted defibrillator device (ICD — a small device placed in your chest to help control dangerous heart rhythms) for at least 12 months

Who may not be able to join:

Your heart or coronary artery disease is currently unstable or not well controlled
You do not have an implanted defibrillator device (ICD)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Registry

ClinicalTrials.gov

Start date

5 November 2025

Est. completion

30 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Quantify the degree of reduced myocardial 18F-mFBG uptake in adult HF subjects with well-characterized coronary heart disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov